Physician profile
Sofia A Lieser
NPI 1033353099
$11,600.53
in general payments reported to CMS, 2019-2025
35 companies · $5,648 in 2025
The $5,648 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $309 · 2021: $546 · 2022: $696 · 2023: $1,102 · 2024: $2,687 · 2025: $5,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,400 · Food and Beverage: $1,939 · Education: $74.99 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,400.00 |
| Food and Beverage | $1,938.90 |
| Education | $74.99 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,400.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $756.62 | 2019-2023 | |
| Intuitive Surgical, INC. | $651.94 | 2019-2023 | Da Vinci Surgical System |
| Pfizer INC. | $417.08 | 2019-2024 | |
| Exeltis, USA INC. | $248.85 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $241.66 | 2022-2025 | Veozah, Myrbetriq |
| Organon LLC | $181.44 | 2022-2025 | Nexplanon |
| Biogen, INC. | $155.50 | 2024-2025 | Zurzuvae, Vumerity |
| Allergan, INC. | $148.61 | 2019-2020 | |
| Agile Therapeutics, INC. | $148.24 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $123.42 | 2023-2025 | Myfembree |
| Minerva Surgical, INC | $113.73 | 2019-2024 | |
| Millicent US INC | $91.41 | 2020-2024 | Intrarosa |
| Myovant Sciences INC. | $89.97 | 2022 | |
| Mylan Pharmaceuticals INC. | $84.55 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $80.46 | 2022-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $77.72 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $66.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.45 | 2019 | |
| Avion Pharmaceuticals | $58.76 | 2019-2023 | Balcoltra |
| Duchesnay USA Incorporated | $47.18 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $39.68 | 2020-2023 | Exparel |
| Medtronic, INC. | $39.33 | 2022-2024 | Venaseal |
| Dilon Technologies, INC. | $36.97 | 2025 | Hemoblast Bellows |
| Molnlycke Health Care US, LLC | $32.43 | 2024 | Mepilex Border Post-Op Ag, Mepilex Border Post-Op |
| Coopersurgical, INC. | $31.31 | 2019-2022 | |
| Convatec INC. | $26.79 | 2023 | |
| Amag Pharmaceuticals, INC. | $26.33 | 2019-2020 | |
| Evofem Biosciences, INC. | $24.73 | 2021 | |
| Novum Pharma, LLC | $21.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.60 | 2024 | |
| Lupin INC. | $15.01 | 2019 | |
| Scynexis, INC. | $14.05 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.70 | 2020 | |
| Channel Medsystems, INC. | $9.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Lieser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.